April 3, 2014

Helix BioPharma Corp. Submits L-DOS47 Investigational New Drug Application with U.S. Food and Drug Administration (PDF)

Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recent submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for approval to initiate a Phase I clinical trial with L-DOS47. The study is entitled “A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer (“NSCLC”).